loading
Alnylam Pharmaceuticals Inc stock is traded at $236.34, with a volume of 1.46M. It is up +5.57% in the last 24 hours and down -3.15% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$224.32
Open:
$220.33
24h Volume:
1.46M
Relative Volume:
1.80
Market Cap:
$28.16B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-108.91
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
-11.25%
1M Performance:
-3.15%
6M Performance:
-12.58%
1Y Performance:
+51.90%
1-Day Range:
Value
$205.87
$244.58
1-Week Range:
Value
$205.87
$264.65
52-Week Range:
Value
$141.97
$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Name
Alnylam Pharmaceuticals Inc
Name
Phone
(617) 551-8200
Name
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Employee
2,230
Name
Twitter
@alnylam
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ALNY's Discussions on Twitter

Compare ALNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.62 28.16B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.07 118.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.21 58.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
560.94 32.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ONC
Beigene Ltd Adr
206.03 22.43B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-31-25 Initiated Redburn Atlantic Buy
Mar-24-25 Upgrade JP Morgan Neutral → Overweight
Nov-12-24 Downgrade Wolfe Research Peer Perform → Underperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-16-24 Upgrade Goldman Neutral → Buy
Feb-16-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-08-23 Initiated Wells Fargo Equal Weight
Oct-11-23 Downgrade Oppenheimer Outperform → Perform
Sep-29-23 Initiated Raymond James Outperform
May-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-26-23 Initiated SMBC Nikko Neutral
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Buy
Sep-09-22 Resumed Morgan Stanley Equal-Weight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-27-22 Downgrade Guggenheim Buy → Neutral
Jun-07-22 Initiated William Blair Outperform
Apr-25-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-01-22 Initiated Citigroup Buy
Feb-03-22 Upgrade Guggenheim Neutral → Buy
Jan-03-22 Upgrade Piper Sandler Neutral → Overweight
Nov-22-21 Upgrade Goldman Neutral → Buy
Nov-22-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-01-21 Upgrade Oppenheimer Perform → Outperform
Oct-04-21 Upgrade UBS Neutral → Buy
Aug-04-21 Downgrade Piper Sandler Overweight → Neutral
Feb-22-21 Downgrade Guggenheim Buy → Neutral
Feb-12-21 Downgrade Citigroup Buy → Neutral
Feb-12-21 Reiterated H.C. Wainwright Buy
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-30-20 Resumed Berenberg Hold
Sep-08-20 Initiated Citigroup Buy
Aug-11-20 Downgrade Oppenheimer Outperform → Perform
May-13-20 Initiated RBC Capital Mkts Sector Perform
May-07-20 Downgrade JP Morgan Overweight → Neutral
Apr-24-20 Resumed Evercore ISI Outperform
Mar-19-20 Initiated Berenberg Buy
Dec-19-19 Reiterated Chardan Capital Markets Buy
Nov-20-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
May-23-19 Resumed Goldman Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Mar-06-19 Upgrade Evercore ISI In-line → Outperform
Mar-05-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19 Initiated UBS Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-13-18 Reiterated Stifel Buy
Aug-07-18 Upgrade Stifel Hold → Buy
May-04-18 Reiterated Stifel Hold
Mar-28-18 Initiated Evercore ISI In-line
View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

pulisher
Apr 08, 2025

Alnylam at 24th Annual Needham Conference: Strategic Growth in Focus By Investing.com - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey

Apr 08, 2025
pulisher
Apr 04, 2025

Is Alnylam Pharmaceuticals Gaining or Losing Market Support? - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Primary Hyperoxaluria Market to Expand Significantly by 2034, - openPR.com

Apr 04, 2025
pulisher
Apr 03, 2025

H.C. Wainwright maintains $500 target on Alnylam stock By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 02, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Alnylam and Tekmira Restructure Relationship and Settle All Litigation - AOL.com

Apr 02, 2025
pulisher
Apr 01, 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Rnai Technology Market Generated Opportunities, Future Scope - openPR.com

Apr 01, 2025
pulisher
Apr 01, 2025

RNAi Leader Alnylam Reveals Growth Strategy at Major Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Pfizer's $11.6 billion Biohaven buy could spark more biotech deals - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 31, 2025

Sanofi, Alnylam win first RNAi approval for hemophilia A and B - PharmaLive

Mar 31, 2025
pulisher
Mar 31, 2025

Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Stifel cuts Alnylam stock price target to $300 from $345 By Investing.com - Investing.com UK

Mar 31, 2025
pulisher
Mar 31, 2025

FDA Approves Sanofi's Hemophilia Drug - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Scotiabank raises Alnylam stock target to $342, maintains rating By Investing.com - Investing.com UK

Mar 31, 2025
pulisher
Mar 31, 2025

Stifel raises Alnylam stock price target to $345 on FDA nod - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn-Atlantic sets $353 target on Alnylam stock with Buy rating - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025 - BioSpace

Mar 31, 2025
pulisher
Mar 29, 2025

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip - simplywall.st

Mar 29, 2025
pulisher
Mar 29, 2025

Groundbreaking HELIOS-B Trial: AMVUTTRA Proves Major Breakthrough for Heart Disease Patients - Stock Titan

Mar 29, 2025
pulisher
Mar 28, 2025

Alnylam’s Qfitlia gets FDA nod for hemophilia treatment By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

FDA approves first-of-its-kind RNA drug for hemophilia - BioPharma Dive

Mar 28, 2025
pulisher
Mar 28, 2025

Alnylam’s Qfitlia gets FDA nod for hemophilia treatment - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Revolutionary Hemophilia Treatment Achieves 90% Bleed Reduction in FDA Approval - Stock Titan

Mar 28, 2025
pulisher
Mar 28, 2025

FDA approves Sanofi’s RNAi drug for hemophilia A and B - Endpoints News

Mar 28, 2025
pulisher
Mar 26, 2025

Alnylam CEO's compensation package continues to grow - NBC Boston

Mar 26, 2025
pulisher
Mar 26, 2025

Alnylam CEO’s compensation package continues to grow - The Business Journals

Mar 26, 2025
pulisher
Mar 26, 2025

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Transthyretin Amyloidosis Treatment Market Detailed In New - openPR

Mar 26, 2025
pulisher
Mar 26, 2025

Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More - BioSpace

Mar 26, 2025
pulisher
Mar 25, 2025

Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com India

Mar 25, 2025
pulisher
Mar 24, 2025

FDA approves new drug to treat protein buildup in the heart - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

FDA OKs Amvuttra To Treat Heart Conditions - The Daily Courier

Mar 24, 2025
pulisher
Mar 24, 2025

RBC Capital holds $330 target on Alnylam stock post-Amvuttra approval - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis - Value The Markets

Mar 24, 2025
pulisher
Mar 24, 2025

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280 - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

JPMorgan raises Alnylam stock rating, lifts target to $328 - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN

Mar 24, 2025
pulisher
Mar 23, 2025

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision - simplywall.st

Mar 23, 2025

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Garg Pushkal
CMO & EVP Dev & Med Affairs
Mar 24 '25
Sale
300.00
5,445
1,633,500
20,221
Garg Pushkal
CMO & EVP Dev & Med Affairs
Mar 21 '25
Sale
285.00
4,321
1,231,485
20,221
PYOTT DAVID E I
Director
Mar 24 '25
Option Exercise
88.95
7,440
661,788
7,576
PYOTT DAVID E I
Director
Mar 24 '25
Sale
299.00
7,440
2,224,560
136
$544.60
price down icon 0.62%
biotechnology ONC
$209.02
price up icon 0.04%
$86.08
price down icon 1.26%
$30.56
price down icon 2.77%
$16.77
price down icon 0.32%
Cap:     |  Volume (24h):